A decade of research has established the phospholipase iPLA 2 ␥ as being involved in cardiomyocyte dysfunction and necrosis leading to heart failure, but the mechanisms by which iPLA 2 ␥ acts and its interaction with the mitochondrial permeability transition pore (mPTP) that is critical for cardiac homeostasis are unclear. New investigations by Moon et al. demonstrate that mitochondria in failing hearts undergo dynamic shifts in PLA 2 isoform expression, leading to a redistribution of eicosanoid composition that contributes to pathologic mPTP opening.
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Heart failure is a common condition defined by the inability of the heart to pump sufficient blood to maintain normal health, due to defects either in contraction by the left ventricle or in relaxation. At the cellular level, human heart failure is characterized by altered energy substrate metabolism, abnormal calcium homeostasis, and mitochondrial dysfunction, leading to CM 2 loss (1). These processes converge in the function of the mitochondrial permeability transition pore (mPTP), a nonselective channel regulated by calcium and other species (2) . As a result, the prolonged opening of mPTP has been implicated in mitochondrial swelling, cytochrome c release, and necrotic cell death; however, the precise mechanism mediating mPTP opening is incompletely understood (1, 2) . A series of investigations by Gross and colleagues have also pointed to a role for the mitochondrial phospholipase isoform iPLA 2 ␥ in these pathological processes (3) (4) (5) (6) . This enzyme cleaves one of the carbon chains from phospholipids to release the fatty acid arachidonic acid (AA), which can be oxidized into signaling-active eicosanoids. Gross and colleagues showed that iPLA 2 ␥ knockout alters mitochondrial lipids, impacting both bioenergetic phenotypes (3) and the extent of damage in a heart failure model (6) . iPLA 2 ␥ knockout also attenuates calcium-induced mPTP opening and cytochrome c release (4). Additionally, iPLA 2 ␥, along with other phospholipases, is activated by cations, reminiscent of the global perturbations observed in heart failure (5) .
More recent findings demonstrated that the PLA 2 isoform type is the rate-limiting step in AA release, lending increased importance to its role in the production of specific eicosanoids (7) , and three eicosanoids have been identified as influencing mPTP function: 14,15-epoxyeicosatrienoic acid (14,15-EET) attenuates myocardial mPTP opening and is protective in heart failure models, whereas 12-and 20-hydroxyeicosatetraenoic acids (12-and 20-HETEs) increase mitochondrial calcium concentration and worsen damage (7, 8) . Unexpectedly, another recent study showed that the consequences of mPTP opening lead to iPLA 2 ␥ activation, raising questions as to the course of events in CM loss. A new study by Moon et al. (9) helps to reconcile these observations, identifying mechanisms through which mitochondrial phospholipases contribute to mitochondrial dysfunction in human heart failure.
Moon et al. (9) suspected that the changing cellular conditions they had observed to activate phospholipases might be the pathological trigger for iPLA 2 ␥ to induce changes in lipid profiles and therefore promote mPTP opening. In other words, increases in cellular calcium concentration activate PLA 2 enzymes to catalyze the hydrolysis of phospholipids and generate AA that is subsequently oxidized to produce eicosanoids, adversely affecting mitochondria in heart failure. To test this hypothesis, the authors examined mitochondria isolated from left ventricular tissues taken from human heart failure patients during placement of ventricular assist devices and compared them to mitochondria from non-failing control hearts. Liquid chromatography-MS/MS-based quantification of eicosanoids demonstrated that addition of calcium to mitochondria from failing hearts induced large increases in production of 5-, 8-, 11-, 12-, and 15-HETEs and reciprocal attenuations of 14,15-EET, in contrast to that observed in control hearts. Levels of the inflammatory prostaglandin PGE 2 increased and cardioprotective prostacyclins decreased in failing myocardium, confirming that mitochondrial eicosanoid composition globally shifts from protective to harmful in this context. Mitochondria from failing hearts also had increased sensitivity to calcium-induced swelling. To establish a mechanistic link between altered eicosanoid profiles and mitochondrial function in failing hearts, mPTP properties were examined in the context of inhibitors of the enzymes involved in eicosanoid biosynthesis and catabolism, the cyclooxygenases, lipoxygenases, and cytochrome P450 monooxygenases. The authors confirmed that HETEs did activate the calcium-induced mPTP opening. Moreover, the lipoxygenase inhibitor baicalein completely abolished calcium-activated mPTP opening in failing hearts, and this inhibition was overcome by co-administration of 12-, 15-, or 20-HETEs.
Next, the authors also tested whether substrate availability might impact eicosanoid profiles in the failing and control mitochondria. Surprisingly, they observed minimal differences in the production of eicosanoids between the two mitochondria after the addition of exogenous deuterated AA. These results suggest that the availability of AA to downstream oxidative enzymes is the rate-limiting step in eicosanoid production and that AA might be directed to different oxidative enzymes in pathological conditions.
To gain insight into this unexpected result, the investigators delved deeper into the function of mitochondrial PLA 2 isoforms in failing and control hearts. Unexpectedly, the authors discovered that calcium-activated AA release and lysophospholipid production in mitochondria from control heart was inhibited by a nonspecific serine hydrolase inhibitor, but not inhibitors of iPLA 2 ␤, iPLA 2 ␥, or cPLA 2 ␣, pointing to activity of an alternative isoform. Column chromatography and characterization of this PLA 2 activity identified cPLA 2 as the predominant isoform. In striking contrast, ϳ50% of the calcium-independent AA release observed in failing heart was blocked by an iPLA 2 ␥ inhibitor. Thus, the altered eicosanoid composition of these two biological systems reflects a change in phospholipase isoform, with cPLA 2 responsible for protective EET production in healthy hearts and iPLA 2 ␥ producing HETEs in mitochondria from failing hearts.
Collectively, these experiments highlight several fascinating concepts regarding iPLA 2 ␥, mitochondrial eicosanoid production, and mPTP opening in heart failure. First, the distribution of PLA 2 isoforms and downstream products is dynamic and dependent on the context of the tissue isolated (e.g. physiologic versus pathophysiologic). Second, changes in the population of PLA 2 enzymes and the resultant redistribution of eicosanoid composition from EET to HETEs contributes to pathologic mPTP opening, mitochondrial swelling, cytochrome c release, and CM dysfunction in heart failure. Third, iPLA 2 ␥ and the downstream enzymes that differentially oxidize AA to generate eicosanoids represent innovative targets for therapeutic intervention. Fourth, this work defines a potential feed-forward mechanism impacting mitochondrial function and CM necrosis. Namely, an increase in mitochondrial calcium concentration and change in membrane potential leads to an activation of PLA 2 activity and change in the population of PLA 2 enzymes. These changes create a shift in mitochondrial eicosanoid profile from protective EET to harmful HETEs that further increase mPTP opening and mitochondrial calcium concentration. This forward spiral continues until mitochondria swell, release cytochrome c, and induce CM death (Fig. 1) .
These new results also prompt additional questions. How is AA oxidation to generate specific eicosanoids controlled? How does iPLA 2 ␥ interact with oxidative enzymes to produce HETEs? What mediates the changes in PLA 2 isoforms? Are there eicosanoid-dependent transcriptional changes in PLA 2 isoforms that differentially regulate changes from cPLA 2 in non-failing hearts to iPLA 2 ␥ in heart failure? Would manipulation of iPLA 2 ␥ or cPLA 2 alter heart failure, and are these findings generalizable to other diseases? Investigations by Gross and colleagues have advanced our understanding of iPLA 2 , and the field looks forward to continued successes in unraveling the biochemical intricacies of phospholipases A 2 and their impact on health and disease. Figure 1 . The balance between mitochondrial cPLA 2 in non-failing myocardium and iPLA 2 ␥ in heart failure dictates eicosanoid composition and thus biological outcome. cPLA 2 produces AA for the generation of protective EET in non-failing myocardium. In heart failure, iPLA 2 ␥ emerges as the predominant PLA 2 to produce AA that is used to generate HETEs. HETEs then alter the opening of mPTP, increasing mitochondrial calcium and enhancing iPLA 2 ␥ activity that continues in a feed-forward spiral leading to mitochondrial swelling and myocyte death.
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